Overview

S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery

Status:
Terminated

Trial end date:
2004-01-01

Target enrollment:
0

Participant gender:
All

Summary

RATIONALE: Some tumors need growth factors produced by the body to keep growing. Suramin may interfere with the growth factor and stop the tumor from growing. PURPOSE: Phase II trial to study the effectiveness of suramin in treating patients with stage III or stage IV adrenocortical cancer.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Southwest Oncology Group

Collaborator:

National Cancer Institute (NCI)

Treatments:

Cortisol succinate
Hydrocortisone
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate
Hydrocortisone hemisuccinate
Suramin

Criteria

DISEASE CHARACTERISTICS: Histologically confirmed adrenocortical carcinoma in Stage III or
IV and incurable by surgery Bidimensionally measurable disease

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: SWOG 0-2 Hematopoietic: WBC
at least 4,000/mm3 Absolute granulocyte count at least 2,000/mm3 Platelet count at least
150,000/mm3 Prothrombin time and partial thromboplastin time no greater than upper limit of
normal (ULN) Hepatic: SGOT and alkaline phosphatase no greater than 2 times ULN Renal:
Creatinine clearance at least 50 mL/min Serum creatinine no greater than ULN Other: No
second malignancy within 5 years except adequately treated basal cell or squamous cell
carcinoma of the skin,in situ carcinoma of the cervix, or other cancer for which patient
has been disease free for 5 years Not pregnant or nursing Effective contraception required
of fertile patients

PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent biologic therapy At least 4 weeks
since prior biologic therapy (one regimen only) Chemotherapy: No concurrent chemotherapy At
least 4 weeks since prior mitotane No other prior chemotherapy allowed Endocrine therapy:
At least 6 weeks since prior hormonal therapy No concurrent hormonal therapy Radiotherapy:
At least 4 weeks since prior radiation therapy (to less than 25% of bone marrow) No
concurrent radiation therapy Surgery: Prior surgery allowed in relapsed patients with no
other prior treatment